Work

Supplementary Figure 1 from Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 319K, Target inhibition after treatments with NVP-BKM120 in vivo. Tumor-bearing MMTV-CreBRCA1f/fp53+/- mice were biopsied before treatment, and tumor tissues harvested within 3 hours after the last treatment. Tissues were fixed and processed for immunohistochemistry with anti-phospho AKT (S473) antibodies. 400 x magnification

DOI: 10.1158/2159-8290.22529226.v1

Authors: Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362538445

Cites:

Cited by:

Related to: 10